Co-stimulatory blockade with belatacept in kidney transplantation

Expert Opinion on Biological Therapy

Volumn 14, Issue 5, 2014, Pages 563-567

  Chopra, Bhavna ^a   Sureshkumar, Kalathil K ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Acute rejection; Co stimulation; Graft survival; Posttransplant lymphoproliferative disorder

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; ABATACEPT; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; BK VIRUS INFECTION; CHRONIC ALLOGRAFT NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; OVERALL SURVIVAL; RENAL PROTECTION; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; T LYMPHOCYTE;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84898720624     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.896332     Document Type: Review

References (18)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-Term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011;11(3):450-62
2. Eckberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitor in renal transplantation. New Engl J Med 2007;357(25):2562-75
3. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11(8):1633-44
4. Budde K, Lehner F, Sommerer C, et al. Conversion form cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012;12(6):1528-40
5. Arora S, Tangirala B, Osaschuk L, Sureshkumar KK. Belatacept: A new biological agent for maintenance immunosuppression in kidney transplantation. Expert Opin Biol Ther 2012;12(7):965-79
6. Yamda A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 13:559-75.2002
7. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010;10(3):535-46
8. Durrback A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplant from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010;10(3):547-57
9. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81
10. Rostaing L, Neumayer HH, Reyes-Acevedo R, et al. Belatacept-versus Cyclosporine-based immuposuppresion in renal transplant recipients with preexisting diabetes. Clin J Am Soc Nephrol 2011;6:2696-704
11. Florman S, Bresnahan B, Chan L, et al. Three year outcomes in black/African American kidney transplant recipients from BENEFIT and BENEFIT-EXT studies. Am Transplant Congress 2011;11:abstract 1091
12. Schnitzler MA, Kalsekar A, L'Italien G, et al. Use of 12-month renal function and baseline clinical factors to predict long-Term graft survival: Application to BENEFIT and BENEFIT-EXT trials. Transplantation 2012;93(2):172-81
13. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppresion with Belataceptbased, corticosteroid-Avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76
14. Rostaing L, Vincenti F, Grinyo J, et al. Long-Term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-Term extension of the BENEFIT Study. Am J Transplant 2013;13:2875-83
15. Charpentier B, Medina Pestana JO, Rial M del C, et al. Long-Term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013;13:2884-91
16. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitorbased regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 2011;6:430-9
17. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active controlled, parallel group study in adult kidney transplant recipients. Am J Transplant 2012;12:210-17
18. Riella LV, Sayegh MH. T-cell co-stimulatory blockade in transplantation: Two steps forward one step back!. Expert Opin Biol Ther 2013;13(11):1557-68